Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of JYP0322 versus platinum-based chemotherapy in previously treated ROS1-positive advanced non-small cell lung cancer
CTR20253358Phase 3Active
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JYP0322 in non-small cell lung cancer (NSCLC), sponsored by Guangzhou JOYO Pharma. Started Nov 2025; status: active.
02
Drugs
JYP0322
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253358.